| Trial ID: | L0994 |
| Source ID: | NCT01780454
|
| Associated Drug: |
Medi-507
|
| Title: |
Renal Allograft Tolerance Through Mixed Chimerism
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01780454/results
|
| Conditions: |
End Stage Renal Disease
|
| Interventions: |
DRUG: MEDI-507|DRUG: Rituximab|RADIATION: Total Body Irradiation|RADIATION: Thymic Irradiation
|
| Outcome Measures: |
Primary: Successful Withdrawal of Immunosuppressive Therapy, The primary endpoint is induction of transient mixed chimerism and renal allograft tolerance without "engraftment syndrome" or "acute kidney injury", 5 years | Secondary: Number of Participants With Engraftment Syndrome, Constellation of symptoms known "Engraftment Syndrome", 5 Years
|
| Sponsor/Collaborators: |
Sponsor: Massachusetts General Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
2
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-03
|
| Completion Date: |
2020-06
|
| Results First Posted: |
2020-09-23
|
| Last Update Posted: |
2021-04-19
|
| Locations: |
Massachusetts General Hospital, Boston, Massachusetts, 02114, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01780454
|
